Home » Newsletters » BioWorld Science

BioWorld Science

Dec. 27, 2000

View Archived Issues

Potent and selective octapeptide sst3 receptor antagonist identified by Swiss, U.S. researchers

Myogen and BASF to codevelop BSF-208075

Zonagen and Wyeth-Ayerst sign human contraceptive vaccine agreement

Oxford GlycoSciences and Pfizer enter biomarker discovery alliance

AstraZeneca continues to make progress across development portfolio

SLIL designs conformationally restricted polyamine analogues for cancer therapy

AstraZeneca seeks FDA approval for pediatric indication of Naropin

EU recommends approval of PegIntron/Rebetol combination for hepatitis C treatment

CeNeS grants license to Shire for dopamine D1 agonist program

Japanese launch of maxacalcitol announced

Inflazyme's novel asthma therapy enters phase II following U.K. approval

R.W. Johnson delays North American phase III trial of influenza inhibitor

Starlix approved by FDA for treatment of type 2 diabetes

Actis for erectile dysfunction approved by FDA for OTC marketing

Once-daily Detrol approved by FDA for treatment of overactive bladder

Novel method for treating autoimmune diseases revealed by UAB Research Foundation

Sumitomo discloses thiourea derivatives with ECE-inhibitory activity

Sumitomo reports quinazoline derivatives with potential for allergic disease treatment

Novel steroid compounds demonstrate anticancer potential

Tanabe Seiyaku claims isoquinoline derivatives with cardiovascular activity

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for Dec. 31, 2025.
Today's news in brief
BioWorld MedTech
BioWorld MedTech briefs for Dec. 31, 2025.
Researchers discover how glioblastoma tumors dodge chemotherapy
BioWorld MedTech
Researchers at the University of Sydney have uncovered a mechanism that may explain why glioblastoma returns after treatment, and the world-first discovery offers...
Shionogi nabs revenue-generating ALS drugs with $2.5B Tanabe pact
BioWorld
Shionogi & Co. Ltd. will acquire global rights to U.S. FDA approved amyotrophic lateral sclerosis therapy edaravone through a $2.5 billion acquisition deal with...
Big pharma taps fast Asia innovation in search of next Keytruda
BioWorld
Speed and innovation from Asia Pacific’s (APAC) biotechnology sector had big pharma scouring the region for the next oncology heir to Keytruda (pembrolizumab),...